Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 9, 2005, Pages 923-928

  Szalay, Ferenc ^a   Folhoffer, Aniko ^a   Horváth, Andrea ^a   Csak, Timea ^a   Speer, Gabor ^a   Nagy, Zsolt ^a   Lakatos, Peter ^a   Horváth, Csaba ^a   Habior, Andrzej ^b   Tornai, Istvan ^c   Lakatos, Peter Laszlo ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Free leptin index; Hepatic osteopathy; Leptin; Osteoporosis; Primary biliary cirrhosis; Soluble leptin receptor

Indexed keywords

LEPTIN; LEPTIN RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR NECK; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; METABOLIC REGULATION; OSSIFICATION; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

AGED; BONE DENSITY; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; FEMALE; FEMUR NECK; HUMANS; LEPTIN; LIVER CIRRHOSIS, BILIARY; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; RECEPTORS, CELL SURFACE;

EID: 23944436423     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200509000-00007     Document Type: Article

References (48)

1. Guanabens N, Pares A, Marinoso L, Brancós MA, Pierra C, Serrano S, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:1356-1362.
2. Vleggar FP, van Buuren HR, Wolfhagen FH, Schalm SW, Pols HA. Prevention and treatment of osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11:617-621.
3. Lakatos PL, Firneisz G, Lakatos P, Horvath C, Szalay F. Follow-up study of bone mineral density in postmenopausal patients with primary biliary cirrhosis. Orv Hetil 2001; 142:503-508.
4. Szalay F, Hegedus D, Lakatos PL, Bajnok E, Tornai I, Lakatos P. High serum osteoprotegerin and low RANKL levels in patients with primary biliary cirrhosis. J Hepatol 2003; 38:395-400.
5. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7:137-142.
6. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodelling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14:819-827.
7. Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 82:97-102.
8. Mitchinson HC, Malcolm AJ, Bassendine MF, James OFW. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988; 94:463-470.
9. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Ebert S. Genetic determinants of bone mass in adults: a twin study. J Clin Invest 1987; 80:700-710.
10. Lakatos LP, Bajnok E, Hegedus D, Toth T, Lakatos P, Szalay F. Vitamin D receptor Bsm I, estrogen receptor alpha gene Pvu II and Xba I and IL-1 receptor-antagonist gene VNTR polymorphism and bone mineral density in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002; 14:733-740.
11. Lakatos PL, Bajnok E, Tornai I, Folhoffer A, Horvath A, Lakatos P, et al. Insulin-like growth factor I (IGF-I) gene microsatellite repeat and collagen type Iα1 Sp1 polymorphism (COLIA1) and bone disease in primary biliary cirrhosis (PBC). Eur J Gastroenterol Hepatol 2004; 16:753-759.
12. Halmos B, Szalay F, Cserniczky T, Nemesanszky E, Lakatos P, Barlage S, et al. Association of primary biliary cirrhosis with vitamin D receptor Bsml genotype in a Hungarian population. Dig Dis Sci 2000; 45:1091-1095.
13. Springer JE, Cole DEC, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118:145-151.
14. Pares A, Guanabens N, Alvarez L, De Osoba MJ, Oriola J, Pons F, et al. Collagen type I alpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001; 33:554-560.
15. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold KR. Endotoxin and cytokine induce expression of leptin, the OB gene product, in hamster. A role for leptin in the anorexia of infection. J Clin Invest 1996; 97:2152-2157.
16. Otte C, Otte JM, Strodthoff D, Bornstein SR, Folsch UR, Moning H, et al. Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes 2004; 112:10-17.
17. Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepatol 2004; 11:91-96.
18. Piche T, Gelsi E, Schneider SM, Hébuterne X, Giudicelli J, Ferrua B, et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002;51:434-439.
19. Breidert M, Zimmermann TF, Schneider R, Ehninger G, Brabant G. Ghrelin/leptin-imbalance in patients with primary biliary cirrhosis. Exp Clin Endocrinol Diabetes 2004; 112:123-126.
20. Garcia-Suarez C, Crespo J, Fernandez-Gil PL, Amado JA, Garcia-Unzueta MT, Pons Romero F. Plasma leptin levels in patients with primary biliary cirrhosis and their relationship with degree of fibrosis. Gastroenterol Hepatol 2004; 27:47-50.
21. Cock TA, Auwerx J. Leptin: cutting the fat off the bone. Lancet 2003; 362:1572-1574.
22. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111:305-317.
23. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Ae Kim C, et al. Serum leptin is a regulator of bone mass. Proc Natl Acad Sci USA 2004; 101:3258-3263.
24. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100:197-207.
25. Thomas T. Leptin: a potential mediator for protective effects of fat mass on bone tissue. Joint Bone Spine 2003; 70:18-21.
26. Thomas T, Burguera B, Melton LJ, Atkinson EJ, O'Fallon WM, Riggs BL, et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001; 29:114-120.
27. Dennison EM, Syddall HE, Fall CH, Javaid MK, Arden NK, Phillips DI, et al. Plasma leptin concentration and change in bone density among elderly men and women: the Hertfordshire Cohort Study. Calcif Tissue Int 2004; 74:401-406.
28. Sahin G, Polat G, Baethis S, Milcan A, Baethdatoethlu O, Erdoethan C, et al. Body composition, bone mineral density, and circulating leptin levels in postmenopausal Turkish women. Rheumatol Int 2003; 23:87-91.
29. Odabasi E, Ozata M, Turan M, Bingol N, Yonem A, Cakir B, et al. Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol 2000; 142:170-173.
30. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaes N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141.
31. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89:47-51.
32. Pereira SP, Bray GP, Pitt PI, Li F, Moniz C, Williams R. Non-invasive assessment of bone mineral density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11:323-328.
33. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21:389-392.
34. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, O'Rouke K, Bailey RJ, Blendis LM, et al. Is the Mayo model for predicting survival useful after introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996; 23:1148-1153.
35. Pares A, Guanabens N, Alvarez L, Monegal A, Caballeria L, Peris P, et al. High osteoprotegerin and low RANKL levels in primary biliary cirrhosis. Relationship with the severity of liver disease but not with osteoporosis [Abstract]. Hepatology 2004; 40 (suppl 1):463A.
36. Giannini E, Romagnoli P, Tenconi GL, Botta F, Malfatti F, Chiarbonello B, et al. High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: relationship with TNF-alpha levels. Dig Dis Sci 2004; 49:275-280.
37. Comlekci A, Akpinar H, Yesil S, Okan I, Ellidokuz E, Okan A, et al. Serum leptin levels in patients with liver cirrhosis and chronic viral hepatitis. Scand J Gastroenterol 2003; 38:779-786.
38. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, Sitaraman SV, et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 2004; 18:1612-1614.
39. Serin E, Ozer B, Gumurdulu Y, Kayaselcuk F, Kul K, Boyacioglu S. Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver. J Gastroenterol 2003; 38:471-476.
40. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36:403-409.
41. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003; 98:2771-2776.
42. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen JM. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41:943-949.
43. Takahashi Y, Okimura Y, Mizuno I, Iida K, Takahashi T, Kaji H, et al. Leptin induces mitogen-activated protein kinase-dependent proliferation of C3H10T1/2 cells. J Biol Chem 1997; 272:12897-12900.
44. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 2001; 142:3546-3553.
45. Thomas T, de Vittoris R, David VN, Vico L, Lafage-Proust MH, Alexandre C. Leptin prevents disuse-induced bone loss in tailsuspended female rats. J Bone Miner Res 2001; 16 (suppl 1):S143.
46. Shaarawy M, Abassi AF, Hassan H, Salem ME. Relationship between serum leptin concentrations and bone mineral density as well as biochemical markers of bone turnover in women with postmenopausal osteoporosis. Fertil Steril 2003; 79:919-924.
47. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Brief Report: effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879-884.
48. Simha V, Zerwekh JE, Sakhaee K, Garg A. Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2002; 87:4942-4945.